-
Something wrong with this record ?
Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic
M. Taborsky, R. Aiglova, M. Lazarova, L. Pavlu, J. Danek, J. Precek, A. Schee, V. Gloger, M. Vicha, T. Skala
Language English Country Czech Republic
Document type Journal Article
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
PubMed
33325457
DOI
10.5507/bp.2020.057
Knihovny.cz E-resources
- MeSH
- Adrenergic beta-Antagonists * therapeutic use MeSH
- Betaxolol MeSH
- Bisoprolol MeSH
- Carbazoles MeSH
- Carvedilol MeSH
- Humans MeSH
- Metoprolol MeSH
- Nebivolol MeSH
- Propanolamines * MeSH
- Retrospective Studies MeSH
- Heart Failure * drug therapy epidemiology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
AIMS: Sub-analysis of a retrospective nation-wide observational analysis of heart failure (HF) epidemiology reported to the Czech National Registry of Reimbursed Health Services between 2012 and 2018 aimed at beta-blockers (BBs) utilization. METHODS AND RESULTS: The beta-blockers were generally used in 81.8% of all patients treated for HF in 2012 (n=52 140); 81.8% in 2013 (n=53 058); 83.1% in 2014 (n=56 221); 82.1% in 2015 (n=57 421); 83.3% in 2016 (n=59 187); 82.2% in 2017 (60 058) and in 81.4% in 2018 (n=60 966). In 2018, the majority of patients treated for HF were prescribed metoprolol (22 974; 30.7%) and bisoprolol (21 001; 28%). Carvedilol was prescribed in 7 331 patients treated for HF (9.8%), nebivolol in 5 392 HF patients. Despite its primary indication, betaxolol was used in 2 341 patients treated for HF (3.1%). All other beta-blockers were used in less than 1% of HF patients. In some of the mostly used BBs, their prescription in patients treated for HF changed in the last years (metoprolol 32.4% in 2012, 30.7% in 2018; bisoprolol 20.3% in 2012, 28% in 2018; carvedilol 18.3% in 2012, 9.8% in 2018; nebivolol 2.5% in 2012, 7.2% in 2018; betaxolol 4.2% in 2012, 3.1% in 2018). CONCLUSION: In an analysis of beta-blockers utilization in all patients treated for heart failure in the given year in the whole country, we have found only slightly lower amount of drug prescription in comparison with specific heart failure registries. This indicates a good translation of current standard of care into common clinical practice. Metoprolol remained the mostly prescribed drug. The prescription of bisoprolol and nebivolol has increased at the expense of carvedilol.
Bata's Regional Hospital Zlin Czech Republic
Cardio center Regional Hospital Karlovy Vary Karlovy Vary Czech Republic
Department of Internal Medicine Military University Hospital Prague Czech Republic
References provided by Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22007891
- 003
- CZ-PrNML
- 005
- 20220323102122.0
- 007
- ta
- 008
- 220309s2021 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2020.057 $2 doi
- 035 __
- $a (PubMed)33325457
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Táborský, Miloš, $d 1962- $7 jn20010310074 $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, 775 20 Olomouc, Czech Republic
- 245 10
- $a Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic / $c M. Taborsky, R. Aiglova, M. Lazarova, L. Pavlu, J. Danek, J. Precek, A. Schee, V. Gloger, M. Vicha, T. Skala
- 504 __
- $a Literatura
- 520 9_
- $a AIMS: Sub-analysis of a retrospective nation-wide observational analysis of heart failure (HF) epidemiology reported to the Czech National Registry of Reimbursed Health Services between 2012 and 2018 aimed at beta-blockers (BBs) utilization. METHODS AND RESULTS: The beta-blockers were generally used in 81.8% of all patients treated for HF in 2012 (n=52 140); 81.8% in 2013 (n=53 058); 83.1% in 2014 (n=56 221); 82.1% in 2015 (n=57 421); 83.3% in 2016 (n=59 187); 82.2% in 2017 (60 058) and in 81.4% in 2018 (n=60 966). In 2018, the majority of patients treated for HF were prescribed metoprolol (22 974; 30.7%) and bisoprolol (21 001; 28%). Carvedilol was prescribed in 7 331 patients treated for HF (9.8%), nebivolol in 5 392 HF patients. Despite its primary indication, betaxolol was used in 2 341 patients treated for HF (3.1%). All other beta-blockers were used in less than 1% of HF patients. In some of the mostly used BBs, their prescription in patients treated for HF changed in the last years (metoprolol 32.4% in 2012, 30.7% in 2018; bisoprolol 20.3% in 2012, 28% in 2018; carvedilol 18.3% in 2012, 9.8% in 2018; nebivolol 2.5% in 2012, 7.2% in 2018; betaxolol 4.2% in 2012, 3.1% in 2018). CONCLUSION: In an analysis of beta-blockers utilization in all patients treated for heart failure in the given year in the whole country, we have found only slightly lower amount of drug prescription in comparison with specific heart failure registries. This indicates a good translation of current standard of care into common clinical practice. Metoprolol remained the mostly prescribed drug. The prescription of bisoprolol and nebivolol has increased at the expense of carvedilol.
- 650 12
- $a beta blokátory $x terapeutické užití $7 D000319
- 650 _2
- $a betaxolol $7 D015784
- 650 _2
- $a bisoprolol $7 D017298
- 650 _2
- $a karbazoly $7 D002227
- 650 _2
- $a karvedilol $7 D000077261
- 650 12
- $a srdeční selhání $x farmakoterapie $x epidemiologie $7 D006333
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a metoprolol $7 D008790
- 650 _2
- $a nebivolol $7 D000068577
- 650 12
- $a propanolaminy $7 D011412
- 650 _2
- $a retrospektivní studie $7 D012189
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Aiglová, Renáta $7 xx0227652 $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, 775 20 Olomouc, Czech Republic
- 700 1_
- $a Lazarová, Marie $7 _AN089526 $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, 775 20 Olomouc, Czech Republic
- 700 1_
- $a Pavlů, Luděk $7 xx0236019 $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, 775 20 Olomouc, Czech Republic
- 700 1_
- $a Daněk, Josef $7 xx0242063 $u Department of Internal Medicine, Military University Hospital, Prague, Czech Republic
- 700 1_
- $a Přeček, Jan, $d 1985- $7 xx0154445 $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, 775 20 Olomouc, Czech Republic
- 700 1_
- $a Schee, Alexandr $7 xx0134780 $u Cardio center, Regional Hospital Karlovy Vary, Karlovy Vary, Czech Republic
- 700 1_
- $a Gloger, Vít $7 xx0209738 $u Bata's Regional Hospital, Zlin, Czech Republic
- 700 1_
- $a Vícha, Marek $7 xx0229304 $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, 775 20 Olomouc, Czech Republic
- 700 1_
- $a Skála, Tomáš $7 xx0137536 $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, 775 20 Olomouc, Czech Republic
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g Roč. 165, č. 4 (2021), s. 402-407
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33325457 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y p $z 0
- 990 __
- $a 20220309 $b ABA008
- 991 __
- $a 20220323102118 $b ABA008
- 999 __
- $a ok $b bmc $g 1773021 $s 1159084
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 165 $c 4 $d 402-407 $e 20201215 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK118 $a Pubmed-20220309
